Table 1 The characteristic of included studies
Study ID | Group | Age(years) | Sex (male/female) | ECOG status(0/≥1) | Regimen/Dose | Sample | Tumor site (colon/rectum) | BRAS mutation status (mutant/wild type) | Main outcomes/endpoint |
|---|---|---|---|---|---|---|---|---|---|
Salazar 2015[21] | Experience | 64(37–77) | 25/19 | 22/22 | capecitabine + BEV(5 mg/kg) | 44 | NA | NA | pCR,safety |
Control | 60(42–78) | 30/16 | 30/16 | capecitabine | 46 | NA | NA | ||
Salazar 2020[22] | Experience | 64(37–77) | 25/19 | 22/22 | capecitabine + BEV(5 mg/kg) | 44 | NA | NA | YpCR,DFS,DRFS,OS |
Control | 60(42–78) | 30/16 | 30/16 | capecitabine | 46 | NA | NA | ||
Qin 2021[23] | Experience | 56.7 ± 11.6 | 214/123 | 116/221 | BEV | 337 | 254/83 | 152/160 | PFS,ORR |
Control | 57.4 ± 11.2 | 190/148 | 110/228 | HLX04 | 338 | 251/87 | 141/171 | ||
Oki 2019[24] | Experience | 64(32–80) | 34/23 | 51/6 | mFOLFOX6 + BEV(5 mg/kg) | 57 | 48/9 | NA | PFS,RR |
Control | 65(42–79) | 34/25 | 51/8 | mFOLFOX6 + CET | 59 | 45/14 | NA | ||
Heinemann 2020[25] | Experience | 64(31–76) | 121/62 | 98/85 | FOLFIRI + BEV(5 mg/kg) | 183 | NA | NA | ORR,PFS,OS |
Control | 65(41–76) | 128/41 | 94/75 | FOLFIRI + CET | 169 | NA | NA | ||
Fischer 2022[26] | Experience | 18–75 | 133/68 | 109/92 | FOLFIRI + BEV | 201 | NA | 177/24 | ORR,PFS,OS |
Control | 18–75 | 146/53 | 106/93 | FOLFIRI + CET | 199 | NA | 175/22 | ||
Stathopoulos 2010[27] | Experience | 67(45–82) | 73/41 | 85/29 | FOLFIRI + BEV(7.5 mg/kg) | 114 | NA | NA | RR,OS,toxicity |
Control | 62(30–87) | 68/40 | 78/30 | FOLFIRI | 108 | NA | NA | ||
Chibaudel 2020[28] | Experience | 57.1(46.0-66.2) | 99/95 | 160/33 | FOLFOX4 + BEV (5 mg/kg) for 24 weeks | 194 | NA | NA | DFS,OS |
Control | 57.2(48.2–66.9) | 124/68 | 161/29 | FOLFOX for 24 weeks | 192 | NA | NA | ||
Bendell 2019[29] | Experience | 63.0(29–81) | 38/47 | 47/48 | BEV combined with mFOLFOX6 for 8cycles | 95 | 77/18 | 45/36 | PFS,ORR,OS |
Control | 64.0(27–82) | 56/38 | 60/34 | VAN 2000 mg(q2w) combined with mFOLFOX6 for 8cycles | 94 | 73/21 | 37/43 | ||
Chakravarthy 2020[30] | Experience | 53.9 ± 9.9 | 112/67 | 109/70 | mFOLFOX6 + BEV(5 mg/kg) for 9 cycles | 179 | NA | NA | OS,DFS,AEs,HRQoL |
Control | 54.3 ± 11.7 | 114/62 | 106/70 | mFOLFOX6 for 9 cycles | 176 | NA | NA | ||
Cunningham 2013[31] | Experience | NA | 39/27 | 48/18 | mFOLFOX6 + BEV(10 mg/kg) | 66 | 38/28 | NA | PFS,OS,ORR |
Control | NA | 47/26 | 44/29 | mFOLFOX6 + CED 20 mg | 71 | 50/21 | NA | ||
Control | NA | 49/22 | 42/29 | mFOLFOX6 + CED 30 mg | 73 | 51/22 | NA | ||
Shitara 2016[32] | Experience | 64(26–78) | 39/19 | 43/15 | FOLFIRI + BEV(5 mg/kg) | 58 | NA | NA | OS,PFS,ORR,safety |
Control | 62(31–82) | 34/25 | 47/12 | FOLFIRI + PAN | 59 | NA | NA | ||
Snoeren 2017[33] | Experience | 62(57–70) | NA | 17/6 | capecitabine + BEV | 39 | 13/14 | NA | DFS,OS,toxicity |
Control | 61(53–63) | NA | 13/11 | capecitabine | 38 | 17/13 | NA | ||
Aparicio 2018[34] | Experience | 80.9(75.2–88.3) | 26/25 | NA | BEV combined with CT, at least 6 months | 51 | 37/14 | NA | ORR,PFS,OS, |
Control | 80.1(75.0-90.6) | 30/21 | NA | Individual CT, at least 6 months | 51 | 37/14 | NA | ||
Hurwitz 2004[35] | Experience | 59.5 | 237/165 | 233/165 | Irinotecan + Fluorouracil + Leucovorin + BEV(5 mg/kg) | 402 | 310/92 | NA | OS,PFS,ORR |
Control | 59.2 | 247/164 | 226/185 | Irinotecan + Fluorouracil + Leucovorin | 411 | 333/78 | NA | ||
Sharf 2022[36] | Experience | 58 | 10/9 | 14/5 | CI + BEV | 19 | 13/3 | NA | PFS,OS,ORR, |
Control | 54 | 10/7 | 12/5 | CI | 17 | 10/5 | NA | ||
Venook 2017[37] | Experience | 59.0(21.8–85.0) | 348/211 | 324/235 | CT + BEV(5 mg/kg) | 559 | 334/142 | NA | OS,PFS,RR |
Control | 59.2(20.8–89.5) | 349/229 | 333/245 | CT + CET | 578 | 355/138 | NA | ||
Passardi 2015[38] | Experience | 66(34–83) | 108/68 | 144/32 | CT + BEV | 176 | 135/41 | 64/91 | OS,PFS,ORR |
Control | 66 (33–82) | 115/79 | 154/40 | CT | 194 | 143/51 | 98/71 | ||
Dotan 2012[39] | Experience | 59(45–78) | 8/4 | 3/9 | capecitabine + oxaliplatin + cetuximab + BEV(7.5 mg/kg) | 12 | NA | 3/7 | RR,TTP,OS |
Control | 58(42–74) | 10/1 | 10/1 | capecitabine + oxaliplatin + cetuximab | 11 | NA | 2/8 | ||
Moehler 2009[40] | Experience | 60(37–80) | 22/7 | 25/4 | CAPIRI + BEV | 29 | 14/15 | NA | RR,toxicity,PFS,OS |
Control | 66(55–81) | 9/8 | 12/5 | CAPIRI | 17 | 10/7 | NA | ||
Cremolini 2016[41] | Experience | 29–75 | 150/102 | 227/25 | FOLFIRI + BEV(5 mg/kg) | 252 | 189/63 | NA | PFS,OS,RR |
Control | 27–75 | 75/47 | 85/37 | FOLFIRI | 122 | 81/41 | NA |